Efficacy and safety of continuing for a total of 48 [standard treatment] or prolonging for a total of 72 [prolonged treatment] weeks of combined treatment of patients receiving Pegasys [peginterferon alfa-2a] and Copegus [ribavirin] who are biochemical responders but virological non-responders at week 12 or week 24.
Phase of Trial: Phase III
Latest Information Update: 27 Feb 2017
At a glance
- Drugs Peginterferon alfa-2a (Primary) ; Ribavirin (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms ProPeg
- 14 Oct 2006 New trial record.